Best practices in assessment of developability of biopharmaceutical candidates

Developability of Biotherapeutics: Computational Approaches

Volumn , Issue , 2015, Pages 155-174

  Hartmann, Steffen ^a   Kocher, Hans P ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; MANUFACTURE; SAFETY ENGINEERING;

AGGREGATION PROPENSITY; BIOLOGICAL PROPERTIES; COMPUTATIONAL COMPONENTS; CONTRACT RESEARCH ORGANIZATIONS; ISOELECTRIC POINT (PI); MANUFACTURING PROCESS; PHYSICO-CHEMICAL PROFILES; POST-TRANSLATIONAL MODIFICATIONS;

RISK ASSESSMENT;

EID: 85010938042     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b19023     Document Type: Chapter

References (24)

1. Jostock, T., and Knopf, H. P. 2012. Mammalian stable expression of biotherapeutics. Meth. Mol. Biol. 899: 227-238.
2. Meyer, H., and Schmidhalter, D. 2012. Microbial expression systems and manufacturing from a market and economic perspective. In Innovation in Biotechnology, ed. E. C. Agbo, 211-250. http://www.intechopen.com/books/innovations-in-biotechnology/microbial-expression-systems-and-manufacturing-from-a-market-and-economic-perspective
3. Zurdo, J. 2013. Developability assessment as an early de-risking tool for biopharmaceu¬tical development. Pharm. Bioprocess. 1: 29-50.
4. Yang, X., Xu, W., Dukleska, S., Benchaar, S., Mengisen, S., Antochshuk, V., Cheung, J., Mann, L., Babadjanova, Z., Rowand, J., Gunawan, R., McCampbell, A., Beaumont, M., Meininger, D., Richardson, D., and Ambrogelly, A. 2013. Developability studies before initiation of process development. Improving manufacturability of monoclonal antibodies. mAbs 5: 787-793.
5. Saxena, V., Panicucci, R., Joshi, Y., and Garad, S. 2009. Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable can¬didates. J. Pharm. Sci. 98: 1962-1979.
6. Jenkins, N., Murphy, L., and Tyther, R. 2008. Post-translational modifications of recom¬binant proteins: Significance for biopharmaceutical. Mol. Biotechnol. 39: 113-118.
7. Geisse, S., and Fux, C. 2009. Recombinant protein production by transient gene trans¬fer into mammalian cells. Meth. Enzymol. 463: 223-238.
8. Rombach-Riegraf, V., Karle, A. C., Wolf, B., Sorde, L., Koepke, S., Gottlieb, S., Krieg, J., Djidja M.-C., Baban, A., Spindeldreher, S., Koulov, A., and Kiessling A. 2014. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. PLoS ONE 9: e86322.
9. Sahin, E., and Roberts, C. J. 2012. Size-exclusion chromatography with multi-angle light scattering for elucidating protein aggregation mechanisms. Methods Mol. Biol. 899: 403-423.
10. Phillips, K., and Hernandez de la Pena, A. 2011. The combined use of the Thermofluor assay and ThermoQ analytical software for the determination of protein stability and buffer optimization as an aid in protein crystallization. Curr. Protoc. Mol. Biol. 94: 10.28.1-10.28.15.
11. Hanke, A. T., and Ottens, M. 2014. Purifying biopharmaceuticals: Knowledge-based chromatographic process development. Trends Biotechnol. 32: 210-220.
12. Lorenz, T., Fiaux, J., Heitmann, D., Gupta, K., Kocher, H., Knopf, H.-P., and Hartmann, S. 2014. Developability assessment of biologics by integrated biologics profiling. Am. Pharm. Rev. http://www.americanpharmaceuticalreview.com/Featured-Articles/167439-Developability-Assessment-of-Biologics-by-Integrated-Biologics-Profiling/.
13. Li, L., Kumar, S., Buck, P. M., Burns, C., Lavoie, J., Singh, S. K., Warne, N. W., Nichols, P., Luksha, N., and Boardman, D. 2014. Concentration dependent viscosity of monoclonal antibody solutions: Explaining experimental behavior in terms of molecu¬lar properties. Pharm. Res. DOI: 10.1007/s 11095-014-1409-0.
14. Ghetie, V., and Ward, E. S. 2000. Multiple roles for the major histocompatibility com¬plex class I related receptor FcRn. Ann. Rev. Immunol. 18: 739-766.
15. Roopenian, D. C., and Akilesh, S. 2007. FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7: 715-725.
16. Strohl, W. R. 2009. Optimization of Fc-mediated effector functions of monoclonal anti¬bodies. Curr. Opin. Biotechnol. 20: 685-691.
17. Bertone, P., and Snyder, M. 2005. Advances in functional protein microarray technol¬ogy. FEBS J. 272: 5400-5411.
18. Ewert, S., Huber, T., Honegger, A., and Plückthun, A. 2003. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325: 531-553.
19. Strohl, W. R., and Strohl, L. M. 2012. Development issues: Antibody stability, devel¬opability, immunogenicity, and comparability. In Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry, 377-403. Oxford: Woodhead Publishing.
20. Rouet, R., Lowe, D., and Christ, D. 2014. Stability engineering of the human antibody repertoire. FEBS Lett. 588: 269-277.
21. Dudgeon, K., Rouet, R., Kokmeijer, I., Schofield, P., Stolp, J., Langley, D., Stock, D., and Christ, D. 2012. General strategy for the generation of human antibody vari¬able domains with increased aggregation resistance. Proc. Natl. Acad. Sci. USA 109: 10879-10884.
22. Lowe, D., Dudgeon, K., Rouet, R., Schofield, P., Jermutus, L., and Christ, D. 2011. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 84: 41-61.
23. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., and Schacht, A. L. 2010. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 9: 203-214.
24. DiMasi, J. A., and Grabowski, H. G. 2007. The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28: 469-479.